Abstract
In all, 134 elderly patients (median age 66 years, range 60–75 years) with newly diagnosed acute promyelocytic leukemia (APL) were enrolled in two successive protocols of the Italian multicenter group GIMEMA. All patients received an identical induction with all-trans retinoic acid and idarubicin; 116 (86%) entered complete remission (CR), two (2%) were resistant and 16 (12%) died during induction. After CR, 106 patients received further therapy whereas 10 did not, because of refusal (n=5) or toxicity (n=5). Consolidation consisted of three chemotherapy courses in the AIDA protocol (AIDA, 67 patients) or, since 1997, of an amended protocol including only the first cycle (amended AIDA, aAIDA, 39 patients). In the AIDA group, 43 patients (64%) completed consolidation, while seven (11%) and 17 (25%) patients were withdrawn after first and second courses, respectively; nine patients (13%) died in CR and 12 (18%) relapsed. In the aAIDA group, all patients received the assigned treatment; two patients (5%) died in CR and six (15%) relapsed. In the AIDA and aAIDA series, the 3-year overall and discase-free survival rates were 81 and 83% (P=NS), 73 and 72% (P=NS), respectively. We highlight here the frequency and severity of complications linked to intensive chemotherapy in this clinical setting and suggest that, in APL of the elderly, less intensive postremission therapy allows significant reduction of severe treatment-related toxicity and may be equally effective.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Warrell Jr RP . Pathogenesis and management of acute promyelocytic leukemia. Annu Rev Med 1996; 47: 555–565.
Frankel SR, Powell BL . Current approaches to acute promyelocytic leukemia. In: Tallman MS, Gordon LI (eds). Diagnostic and Therapeutic Advances in Hematologic Malignancies. Boston: Kluwer Academic Publishers, 1999, pp 125–153.
Degos L, Wang ZY . All trans retinoic acid in acute promyelocytic leukemia. Oncogene 2001; 20: 7140–7145.
Tallman MS, Nabhan C, Feusner JH, Rowe JM . Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759–767.
Avvisati G, Mele A, Stazi MA, Vegna ML, Pasquini P, Mandelli F . Epidemiology of acute promyelocytic leukemia in Italy. Ann Oncol 1991; 2: 405–408.
Estey E, Thall PF, Pierce S, Kantarjian H, Keating M . Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483–490.
Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014–1021.
Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021–1028.
Soignet S, Fleischauer A, Polyak T, Heller G, Warrell Jr RP . All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol 1997; 40(Suppl): S25–S29.
Asou N, Adachi K, Tamura J, Kanamaru A, Kagayama S, Hiraoka A et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16: 78–85.
Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH . Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93: 4131–4143.
Sanz MA, Martin G, Rayon C, Esteve J, Gonzales M, Diaz-Mediavilla J et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα positive acute promyelocytic leukemia. Blood 1999; 94: 3015–3021.
Wang Z, Sun G, Shen Z, Chen S, Chen Z . Differentiation therapy for acute promyeloctyc leukemia with all-trans retinoid acid: 10-year experience of its application. Chin Med J 1999; 112: 963–967.
Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192–1200.
Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000; 14: 1362–1370.
Latagliata R, Avvisati G, Lo Coco F, Petti MC, Diverio D, Spadea A et al. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged >60 years. Ann Oncol 1997; 8: 1273–1275.
Latagliata R, Petti MC, Mandelli F . Acute myeloid leukemia in the elderly: ‘per aspera ad astra’? Leukamia Res 1999; 84: 814–819.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British cooperative group. Ann Intern Med 1985; 103: 620–625.
Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225–2229.
Chomczynsky P, Sacchi N . Single step method of RNA isolation by acid guanidium thiocyanate–phenol chloroform extraction. Ann Biochem 1987; 162: 156–159.
Diverio D, Riccioni R, Pistilli A, Buffolino S, Avvisati G, Mandelli F et al. Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia. Leukemia 1996; 10: 1214–1216.
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170.
Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247–1253.
Visani G, Buonamici S, Malagola M, Isidori A, Piccaluga PP, Martinelli G et al. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study. Leukemia 2001; 15: 1696–1700.
Douer D, Estey E, Santillana S, Bennet JM, Lopez-Bernstein G, Boehm K et al. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood 2001; 97: 73–80.
Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH et al. Experience with gemtuzumab ozogamycin (‘mylotarg’) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222–4224.
Dombret H, Fenaux P, Soignet SL, Tallman MS . Established practice in the treatment of patients with acute promyelocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002; 39(Suppl 1): 8–13.
Latagliata R, Petti MC, Fenu S, Mancini M, Spiriti MA, Breccia M et al. Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002; 99: 822–824.
Acknowledgements
This work was supported by grants from Associazione Italiana contro le Leucemie (AIL), Ministero della Università e della Ricerca (MIUR) and Ministero della Salute.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Mandelli, F., Latagliata, R., Avvisati, G. et al. Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 17, 1085–1090 (2003). https://doi.org/10.1038/sj.leu.2402932
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402932
Keywords
This article is cited by
-
Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide
Journal of Cancer Research and Clinical Oncology (2020)
-
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
Leukemia (2020)
-
Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia
Scientific Reports (2019)
-
Management of patients with acute promyelocytic leukemia
Leukemia (2018)
-
Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia
International Journal of Hematology (2018)